 |
|
|
|
|
Hormone Therapy Shows Little Benefit Against Prostate Cancer
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 | 3 In fact, 19.9 percent of those taking PADT died of their prostate cancer within 10 years, compared with only 17.4 of those on the waiting approach.
A second study, this one presented at the European Society for Medical Oncology Lugano conference, found that the number of prostate tumor cells circulating in a patient's bloodstream can predict how effective the treatment is. On average, the fewer the circulating tumor cells, said researchers from the Royal Marsden NHS Foundation Trust in the United Kingdom, the longer the survival.
More information
Text Continues Below
Visit the National Cancer Institute for more on prostate cancer.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 7/8/2008
|
|
SOURCES: Siu-Long Yao, M.D., clinical assistant professor, medicine, Cancer Institute of New Jersey, New Brunswick; Ronald D. Ennis, M.D., director, radiation oncology, St. Luke's Roosevelt Hospital, Continuum Cancer Centers of New York, New York City; Otis Brawley, M.D., chief medical officer, American Cancer Society, Atlanta; July 9, 2008, Journal of the American Medical Association
|
.gif)
